ArticleHemaSphere2020

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.

Kirill V Lepik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.